Literature DB >> 26628987

The miR-101/RUNX1 feedback regulatory loop modulates chemo-sensitivity and invasion in human lung cancer.

Xianghui Wang1, Yihua Zhao2, Haiyun Qian3, Jiangping Huang3, Fenghe Cui3, Zhifu Mao1.   

Abstract

The deregulation of miR-101 has been implicated in multiple cancer types including lung cancer, but the exact role, mechanisms and how silencing of miR-101 remain elusive. Here we confirmed miR-101 downregulation in lung cancer cell lines and patient tissues. Restored miR-101 expression remarkably sensitized lung cancer cells to chemotherapy and inhibited invasion. Mechanistically, we indicated that miR-101 inversely correlated with RUNX1 expression, and identified RUNX1 as a novel target of miR-101. RUNX1 impaired the effects of miR-101 on chemotherapeutic sensitization and invasion inhibition. Moreover, RUNX1 knockdown resulted into increase of miR-101 expression and elevation of luciferase activity driven by miR-101 promoter in lung cancer cells, suggesting RUNX1 negatively transcriptionally regulated miR-101 expression via physically binding to miR-101 promoter. These findings support that miR-101 downregulation accelerates the progression of lung cancer via RUNX1 dependent manner and suggest that miR-101/RUNX1 feedback axis may have therapeutic value in treating refractory lung cancer.

Entities:  

Keywords:  RUNX1; chemotherapy; invasion; lung cancer; miR-101

Year:  2015        PMID: 26628987      PMCID: PMC4658876     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  30 in total

1.  MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.

Authors:  Ji-Guang Zhang; Jian-Feng Guo; Dong-Lei Liu; Quan Liu; Jian-Jun Wang
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

2.  Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF.

Authors:  Nahoko Nishimoto; Shunya Arai; Motoshi Ichikawa; Masahiro Nakagawa; Susumu Goyama; Keiki Kumano; Tsuyoshi Takahashi; Yasuhiko Kamikubo; Yoichi Imai; Mineo Kurokawa
Journal:  Blood       Date:  2011-07-14       Impact factor: 22.113

Review 3.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

4.  RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast differentiation.

Authors:  Woosook Kim; David A Barron; Rebeca San Martin; Keith S Chan; Linda L Tran; Feng Yang; Steven J Ressler; David R Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

Review 5.  The RUNX genes: gain or loss of function in cancer.

Authors:  Karen Blyth; Ewan R Cameron; James C Neil
Journal:  Nat Rev Cancer       Date:  2005-05       Impact factor: 60.716

Review 6.  Acquired resistance to TKIs in solid tumours: learning from lung cancer.

Authors:  D Ross Camidge; William Pao; Lecia V Sequist
Journal:  Nat Rev Clin Oncol       Date:  2014-07-01       Impact factor: 66.675

7.  Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression.

Authors:  Lixin Wang; Joan S Brugge; Kevin A Janes
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-22       Impact factor: 11.205

8.  MicroRNA-101-mediated Akt activation and estrogen-independent growth.

Authors:  M Sachdeva; H Wu; P Ru; L Hwang; V Trieu; Y-Y Mo
Journal:  Oncogene       Date:  2010-10-18       Impact factor: 9.867

9.  Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer.

Authors:  Cornelia Johanna Franziska Scheitz; Tae Seung Lee; David James McDermitt; Tudorita Tumbar
Journal:  EMBO J       Date:  2012-10-02       Impact factor: 11.598

Review 10.  Core binding factor at the crossroads: determining the fate of the HSC.

Authors:  Kevin A Link; Fu-Sheng Chou; James C Mulloy
Journal:  J Cell Physiol       Date:  2010-01       Impact factor: 6.384

View more
  10 in total

1.  MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells.

Authors:  Gillian Browne; Julie A Dragon; Deli Hong; Terri L Messier; Jonathan A R Gordon; Nicholas H Farina; Joseph R Boyd; Jennifer J VanOudenhove; Andrew W Perez; Sayyed K Zaidi; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Tumour Biol       Date:  2016-01-09

2.  Runt-related transcription factor 1 contributes to lung cancer development by binding to tartrate-resistant acid phosphatase 5.

Authors:  Changjun He; Xue Bai; Yingbin Li; Haobo Sun; Xianglong Kong; Bicheng Fu; Lantao Chen; Kaibin Zhu; Pengju Li; Shidong Xu
Journal:  Cell Cycle       Date:  2019-10-25       Impact factor: 4.534

3.  Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma.

Authors:  Xujie Gao; Yupeng Wu; Wenwen Yu; Hui Li
Journal:  Oncotarget       Date:  2016-12-06

4.  Computational analysis of the mesenchymal signature landscape in gliomas.

Authors:  Orieta Celiku; Anita Tandle; Joon-Yong Chung; Stephen M Hewitt; Kevin Camphausen; Uma Shankavaram
Journal:  BMC Med Genomics       Date:  2017-03-09       Impact factor: 3.063

5.  Increased expression of RUNX1 in clear cell renal cell carcinoma predicts poor prognosis.

Authors:  Yang Fu; Shanshan Sun; Xiaojun Man; Chuize Kong
Journal:  PeerJ       Date:  2019-10-02       Impact factor: 2.984

6.  MicroRNA-101 Protects Against Cardiac Remodeling Following Myocardial Infarction via Downregulation of Runt-Related Transcription Factor 1.

Authors:  Xidong Li; Shouwen Zhang; Mingguang Wa; Zhonghua Liu; Shunpeng Hu
Journal:  J Am Heart Assoc       Date:  2019-11-26       Impact factor: 5.501

7.  Elevated RUNX1 is a prognostic biomarker for human head and neck squamous cell carcinoma.

Authors:  Xiaodong Feng; Zhiwei Zheng; Yi Wang; Guanghui Song; Lu Wang; Zhijun Zhang; Jinxia Zhao; Qing Wang; Limin Lun
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-26

8.  miR-302a-5p/367-3p-HMGA2 axis regulates malignant processes during endometrial cancer development.

Authors:  Jian Ma; Da Li; Fan-Fei Kong; Di Yang; Hui Yang; Xiao-Xin Ma
Journal:  J Exp Clin Cancer Res       Date:  2018-02-01

9.  Rasip1 is a RUNX1 target gene and promotes migration of NSCLC cells.

Authors:  Yan Chen; Lin Zhang; Lei Liu; Shixiu Sun; Xuyang Zhao; Yueyuan Wang; Yujie Zhang; Jun Du; Luo Gu
Journal:  Cancer Manag Res       Date:  2018-10-12       Impact factor: 3.989

10.  Astragalus IV Undermines Multi-Drug Resistance and Glycolysis of MDA-MB-231/ADR Cell Line by Depressing hsa_circ_0001982-miR-206/miR-613 Axis.

Authors:  Hongchang Li; Zhihua Xia; Limin Liu; Gaofeng Pan; Junbin Ding; Jiazhe Liu; Jie Kang; Jindong Li; Daowen Jiang; Weiyan Liu
Journal:  Cancer Manag Res       Date:  2021-07-22       Impact factor: 3.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.